The Hindu Business Line : United Biotech in pact to sell Swedish amino acid tablets

New Delhi June 19 United Biotech's speciality division has entered into an in-licensing agreement for Swedish firm Recip AB's dialysis sparing amino acid tablets.

The five-year exclusive agreement gives the 10-year-old pharma company of the United Group of Companies marketing rights for the privately held Recip's registered drug, Aminess N tablets, in India.

"This will afford us the chance to enter the niche Indian nephrology segment market worth Rs 300 crore of which amino acids contributes to about Rs 50 crore. We aim to capture at least 20 per cent share of the market for amino acids and also enter the nephrology segment with a basket of products both in-licensed and locally manufactured," said Mr R.K. Dewan, Vice-President - Marketing, UB in a company statement.

According to United Biotech, regular intake of the tablet reduces the need for frequent dialysis and also delays the need for dialysis in renal patients.

"A renal dietician's greatest challenge today is meeting the patient's nutritional needs and improving the quality of life. Aminess N helps meet both these requirements," he added.

The company claims that several studies have indicated that supplementing the diet of haemodialysis patients with a composition of essential amino acids (Aminess N), leads to an increase in serum albumin levels, or what's often referred to as albumin — the essential plasma protein that maintains the osmotic pressure for proper distribution of body fluids between intravascular compartments and body tissues.